NovaTarg is awarded an SBIR Phase 2b grant to support the early development of NT1195 for Type 2 Diabetes (T2D) in patients with kidney disease. With this funding will perform detailed pharmacology in diabetic monkeys, safety studies to support an exploratory IND filing and PK studies in humans. Drug distribution will be studied in human volunteers, as well as T2D patients with and without normal kidney function
NovaTarg is approved for a $250,000 loan from the NC Biotech Center
NT1195 is selected as a drug candidate for the treatment of Type 2 Diabetes in patients with impaired renal function. IND-enabling studies begin.
NovaTarg has received $3.2 million in SBIR grant funding to further its discovery of tissue selective AMPK activators. NovaTarg plans to progress drug candidates for polycystic Kidney Disease and Type 2 Diabetes during this coming year.